In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Banner Year For Pharma: M&A Tops 2009 Merger Mania

Executive Summary

Fourteen deals have been signed so far in 2014 with an up-front value of $1 billion or more. The standout year for pharma M&A is already more valuable than 2009, the year Pfizer bought Wyeth and Merck acquired Schering-Plough.


Related Content

2016 Pharma Dealmaking: Waiting On The High-Value Deals
Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes
Biopharma Dealmaking Quarterly Statistics, Q3 2014
Getting More From Less: Will Spin-Offs Rise Post-Shire/AbbVie?
VC Outlook Positive On Biotech IPO, M&A Activity
Biopharma Dealmaking Quarterly Statistics, Q2 2014
Actavis’ Big Bet On A Diversified Hybrid Model
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts